Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Breast 2Dermatologic 1

Conditions

Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × tetrathiomolybdate × Gastrointestinal × Clear all
NCT00176800 2016-08-22

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

University of Michigan Rogel Cancer Center

Phase 2 Completed
69 enrolled 7 charts
Gastrointestinal

Esophageal Neoplasms

NCT00176774 2012-02-07

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

University of Michigan Rogel Cancer Center

Phase 2 Completed
24 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00006332 2005-06-24

Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate

National Center for Research Resources (NCRR)

Phase 2 Completed
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡